EIF2AK4 and hydrops fetalis: Through a comprehensive analysis of the mechanism of action of HF, a tRNA synthetase inhibitor that has progressed to phase 2 clinical trials for various indications, our work reveals a vulnerability of the GCN2 branch of the ISR.